Clinical trial shows promising result for patients AND investors

​ ​ ​ ​

​ ​ Brain Cancer Patient from Phase 1 Clinical Trial Remains Cancer Free The NASDAQ stock exchange is abundant with emerging growth biotech stocks, but there is one company on our radar that is targeting the most aggressive type of brain cancer. They IPO'd at $4 per share and expect to initiate their Phase II clinical trial during Q2 of 2021. As of November 2020, a patient from their Phase 1 clinical trial for the treatment of glioblastoma multiforme ("GBM"), remains cancer free. GBM is the most aggressive type of brain cancer that led to the death of Senator Ted Kennedy, Senator John McCain, and President Joe Biden's son. As of today, there are no effective therapies approved to treat this disease. We've put together a detailed report on why we believe it offers investors a unique opportunity in the biotech space. Click here to read the full release from the featured company and learn more about its capabilities. The image on the left is pre-treatment and the one on the right is 6-months post-treatment. ​ ​ ​ ​ ​ ​